Elected officials have been publicly bludgeoning drugmakers they say have used monopoly power to jack up drug prices. Meanwhile, in the background, a generic drugmaker is turning the argument against a competitor, accusing it of pulling a fast one on the FDA to win approval of a drug and setting itself and its partners up to control the market.